Arca
Skip to content

Pyruvate kinase deficiency

Drug research and approvals for pyruvate kinase deficiency: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 1 studies of pyruvate kinase deficiency are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, FDA has 1 approved and 2 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 1
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 1
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 1 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Aug 17, 2023A rollover study to provide continued access to mitapivat for participants who previously participated in an agios-sponsored mitapivat studyMITAPIVAT (AG-348)Agios PharmaceuticalsOngoing
Mar 9, 2023A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of mitapivat in pediatric subjects with pyruvate…MITAPIVAT (AG-348)Agios PharmaceuticalsOngoing
Dec 23, 2021A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of mitapivat in pediatric subjects with pyruvate…MITAPIVAT (AG-348)Agios PharmaceuticalsOngoing
Jan 9, 2019An open-label, multicenter, extension study of ag 348 in adult subjects with pyruvate kinase deficiency previously enrolled in ag-348 studiesMITAPIVAT (AG-348)Agios PharmaceuticalsClosed
May 17, 2018A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ag-348 in not regularly transfused adult subjects with…AG-348Agios PharmaceuticalsClosed
Apr 18, 2018An open-label study to evaluate the efficacy and safety of ag-348 in regularly transfused adult subjects with pyruvate kinase (pk) deficiencyAG-348Agios PharmaceuticalsClosed

FDA Orphan Designations

Approved first, then open designations, newest first
Feb 17, 2022PyrukyndTreatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiencyAgios Pharmaceuticals, Inc.Approved
Mar 7, 2023Autologous CD34+ cells edited with CRISPR/Cas9 and…Treatment of Pyruvate Kinase DeficiencyConsorcio Centro de Investigación Biomédica en Red (CIBER)Designated
Mar 23, 2016lentiviral vector containing the human liver and erythroid…Treatment of pyruvate kinase deficiency.Rocket Pharmaceuticals, Inc.Designated

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Nov 9, 2022Pyrukyndmitapivat · orphanAgios Netherlands B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.